Results 21 to 30 of about 23,157 (220)

Post-Catalytic Complexes with Emtricitabine or Stavudine and HIV-1 Reverse Transcriptase Reveal New Mechanistic Insights for Nucleotide Incorporation and Drug Resistance

Molecules, 2020
Human immunodeficiency virus 1 (HIV-1) infection is a global health issue since neither a cure nor a vaccine is available. However, the highly active antiretroviral therapy (HAART) has improved the life expectancy for patients with acquired ...
Nicole Bertoletti, Albert H. Chan, Raymond F. Schinazi, Karen S. Anderson   +3 more
doaj   +1 more source

Assessment of Gastrointestinal Adverse Effects during the First Six Months of “Biktarvy” Antiretroviral Therapy: Age-Related Patterns and Their Relation with Changes of 5 kg Weight Loss/Gain in the Initial Treatment Period

Diseases, 2023
Background: The battle against HIV has led to the development of antiretroviral therapy (ART), including BIKTARVY®, which combines three potent agents.
Madalina-Ianca Suba, Simona-Alina Abu-Awwad, Ovidiu Rosca, Mirela-Mădălina Turaiche, Bogdan Hogea, Ahmed Abu-Awwad, Razvan Nitu, Voichita Elena Lazureanu   +7 more
doaj   +1 more source

Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid

Southern African Journal of HIV Medicine, 2021
Background: Blood-cerebrospinal fluid (CSF) barrier transporters affect the influx and efflux of drugs. The antiretrovirals tenofovir and emtricitabine may be substrates of blood-brain barrier (BBB) and blood-CSF barrier transporters, but data are ...
Eric H. Decloedt, Phumla Z. Sinxadi, Lubbe Wiesner, John A. Joska, David W. Haas, Gary Maartens   +5 more
doaj   +1 more source

Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients

Medicine, 2016
To assess the safety and efficacy of rilpivirine in combination with emtricitabine and tenofovir (RPV/FTC/TDF) as a once-daily single-tablet regimen (STR) in HIV-1-infected children and adolescents we performed a multicenter case series study of HIV-1 ...
Lola Falcón-Neyra, C. Palladino, M. N. Navarro Gómez, P. Soler-Palacín, M. González-Tomé, S. J. de Ory, M. Frick, C. Fortuny, A. Noguera-Julian, Elena Moreno, J. Santos, P. Olbrich, L. López-Cortés, V. Briz, O. Neth   +14 more
semanticscholar   +1 more source

Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age

HIV Medicine, 2022
Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is an effective treatment for HIV‐1 infection; however, clinical trial data in older people living with HIV (PLWH) are lacking.
F. Maggiolo, G. Rizzardini, J. Molina, F. Pulido, S. De Wit, L. Vandekerckhove, J. Berenguer, M. D’Antoni, C. Blair, S. Chuck, D. Piontkowsky, Hal Martin, R. Haubrich, I. Mcnicholl, J. Gallant   +14 more
semanticscholar   +1 more source

Real World Data on Forgiveness to Uncomplete Adherence to Bictegravir/ Emtricitabine/Tenofovir Alafenamide

Journal of the International Association of Providers of AIDS Care, 2022
Background: forgiveness is the ability of a given regimen to maintain complete viral suppression despite a documented imperfect adherence. We explored forgiveness of bictegravir/emtricitabine/tenofovir alafenamide.
F. Maggiolo, D. Valenti, Rodolfo Teocchi, L. Comí, E. di Filippo, M. Rizzi   +5 more
semanticscholar   +1 more source

High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I

AIDS (London), 2022
Objective: We investigated the prevalence of preexisting M184V/I and associated risk factors among clinical trial participants with suppressed HIV and evaluated the impact of M184V/I on virologic response after switching to bictegravir/emtricitabine ...
P. Sax, Kristen Andreatta, J. Molina, E. Daar, D. Hagins, Rima K. Acosta, M. D’Antoni, Silvia Chang, Ross Martin, Hui C. Liu, C. Blair, I. Mcnicholl, J. Gallant, Sean E. Collins, Hal Martin, K. White   +15 more
semanticscholar   +1 more source

Raltegravir, tenofovir, and emtricitabine in an HIV-Infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver Toxicity

European Journal of Medical Research, 2010
Background in HIV-infected patients with HCV-related chronic hepatitis, liver impairment and drug toxicity may substantially reduce the number of possible therapeutic options.
Ortu F, Weimer LE, Floridia M, Manconi PE   +3 more
doaj   +1 more source

Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet HIV, 2021
Summary Background In DISCOVER, a multinational, randomised controlled trial, emtricitabine and tenofovir alafenamide compared with emtricitabine and tenofovir disoproxil fumarate showed non-inferior efficacy for HIV prevention and improved bone mineral ...
O. Ogbuagu, P. Ruane, D. Podzamczer, Laura Salazar, K. Henry, D. Asmuth, D. Wohl, R. Gilson, Yongwu Shao, R. Ebrahimi, S. Cox, A. Kintu, Christoph C Carter, M. Das, J. Baeten, D. Brainard, G. Whitlock, J. Brunetta, G. Kronborg, C. Spinner   +19 more
semanticscholar   +1 more source

RP-HPLC method development and validation for the estimation of Emtricitabine, Bictegravir and Tenofovir alafenamide in bulk and pharmaceutical dosage form

Journal of Taibah University for Science, 2019
A new simple, accurate, precise RP-HPLC [reverse phase high performance liquid chromatography] method was developed for the simultaneous estimation of the Emtricitabine, Bictegravir and Tenofovir alafenamide in pharmaceutical dosage form.
Tej Kumar Kokkirala, Duvvuri Suryakala
doaj   +1 more source